BET proteins are emerging targets for cancer therapy.11 BET proteins regulate transcription and appear to be utilized during cancer progression to epigenetically reprogram both blood and solid cancers.12 Small-molecule inhibitors of BET proteins are in clinical trials but preclinical models already suggest that combination therapies will be needed to further the efficacy of BET inhibitors (BETIs). The gene discussed is DNER; the disease is cancer.